Last reviewed · How we verify
Gadoterate (Dotarem/Clariscan)
Gadoterate (Dotarem/Clariscan) is a Gadolinium-based contrast agent Small molecule drug developed by Bayer. It is currently FDA-approved for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including cardiovascular and abdominal applications. Also known as: Gadoterate.
Gadoterate is a gadolinium-based contrast agent that accumulates in tissues and enhances MRI signal to improve visualization of anatomical structures and lesions.
Gadoterate is a gadolinium-based contrast agent that accumulates in tissues and enhances MRI signal to improve visualization of anatomical structures and lesions. Used for MRI contrast enhancement for central nervous system imaging, MRI contrast enhancement for body imaging including cardiovascular and abdominal applications.
At a glance
| Generic name | Gadoterate (Dotarem/Clariscan) |
|---|---|
| Also known as | Gadoterate |
| Sponsor | Bayer |
| Drug class | Gadolinium-based contrast agent |
| Target | Water protons (via paramagnetic gadolinium ion) |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
Gadoterate is a macrocyclic gadolinium chelate complex that distributes into the extracellular space following intravenous injection. The paramagnetic gadolinium ion shortens T1 and T2 relaxation times of nearby water protons, producing bright signal enhancement on T1-weighted MRI images. This allows improved delineation of tissues, blood vessels, and pathological lesions with altered perfusion or permeability.
Approved indications
- MRI contrast enhancement for central nervous system imaging
- MRI contrast enhancement for body imaging including cardiovascular and abdominal applications
Common side effects
- Headache
- Dizziness
- Nausea
- Injection site reactions
- Nephrogenic systemic fibrosis (rare, in severe renal impairment)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gadoterate (Dotarem/Clariscan) CI brief — competitive landscape report
- Gadoterate (Dotarem/Clariscan) updates RSS · CI watch RSS
- Bayer portfolio CI
Frequently asked questions about Gadoterate (Dotarem/Clariscan)
What is Gadoterate (Dotarem/Clariscan)?
How does Gadoterate (Dotarem/Clariscan) work?
What is Gadoterate (Dotarem/Clariscan) used for?
Who makes Gadoterate (Dotarem/Clariscan)?
Is Gadoterate (Dotarem/Clariscan) also known as anything else?
What drug class is Gadoterate (Dotarem/Clariscan) in?
What development phase is Gadoterate (Dotarem/Clariscan) in?
What are the side effects of Gadoterate (Dotarem/Clariscan)?
What does Gadoterate (Dotarem/Clariscan) target?
Related
- Drug class: All Gadolinium-based contrast agent drugs
- Target: All drugs targeting Water protons (via paramagnetic gadolinium ion)
- Manufacturer: Bayer — full pipeline
- Therapeutic area: All drugs in Diagnostic Imaging
- Indication: Drugs for MRI contrast enhancement for central nervous system imaging
- Indication: Drugs for MRI contrast enhancement for body imaging including cardiovascular and abdominal applications
- Also known as: Gadoterate